Sarcomas

Filip Janku, MD, PhD highlighted a dose-escalated approach of ripretinib and how it yielded a progression-free survival benefit in patients with gastrointestinal stromal tumor across all lines of treatment in a phase 1 study.

December 14, 2020 — A link between tumor growth rate and clinical outcomes was established in patients with sarcoma who received treatment with immunotherapy or targeted therapy.

November 30, 2020 - Dose escalation with ripretinib following disease progression on the 150-mg daily dose led to a clinically meaningful benefit in patients with advanced gastrointestinal stromal tumor.

November 30, 2020 - The FDA has approved the Sonalleve MR-guided high-intensity focused ultrasound (MR-HIFU) system for the treatment of patients with osteoid osteoma in the extremities.

Selinexor demonstrated a statistically significant improvement in progression-free survival compared with matching placebo in patients with advanced unresectable dedifferentiated liposarcoma, following at least 2 prior treatments.

R. Lor Randall, MD, FACS, discusses limb salvage surgeries that have been made possible through 3D printing, and the technological advances that are helping to increase precision and turnaround times.

November 24, 2020 — The FDA has granted an orphan drug designation to devimistat for the treatment of patients with soft tissue sarcoma.

November 24, 2020 - Pexidartinib was found to result in prolonged efficacy with favorable safety in patients with tenosynovial giant cell tumors, according to long-term data from a pooled analysis of 3 cohorts of patients who received the agent.

November 23, 2020 - Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations.

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Marilyn M. Bui, MD, PhD, highlights the importance of pathology in sarcoma and how it is the cornerstone of precision medicine.

November 18, 2020 - The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma.

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.

John Zalcberg, ​PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

William D. Tap, MD, discusses future research efforts in sarcoma.

Single-agent selinexor resulted in a statistically significant prolongation of progression-free survival in patients with advanced unresectable dedifferentiated liposarcoma, meeting the primary end point of the phase 3 SEAL trial.

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

William D. Tap, MD, discusses the importance of ​community and academic collaboration in sarcoma.

R. Lor Randall, MD, FACS, highlights the various data presented at the annual MSTS meeting and their implications for the future of sarcoma treatment.

César Serrano-García, MD, PhD, highlights ripretinib and the meaningful benefit it provides as a fourth- and later-line therapy in patients with advanced gastrointestinal stromal tumor who harbor KIT or PDGFRA mutations.